Morquio's syndrome: Difference between revisions

Jump to navigation Jump to search
Irfan Dotani (talk | contribs)
No edit summary
Dayana Davidis (talk | contribs)
No edit summary
 
Line 21: Line 21:


==Overview==
==Overview==
'''Morquio syndrome''' (referred to as '''[[mucopolysaccharidosis]] IV''' or '''Morquio''')  is a [[mucopolysaccharide]] storage disease (see also [[lysosomal storage disorder]]), usually inherited. It is a relatively rare [[dwarfism]] with serious consequences. When the body cannot process certain types of mucopolysaccharides, they build up or are eliminated, causing various symptoms.  
'''Morquio syndrome''' (referred to as '''[[mucopolysaccharidosis]] IV''' or '''Morquio''')  is a [[mucopolysaccharide]] storage disease (see also [[lysosomal storage disorder]]), usually inherited. Morquio is a relatively rare metabolic disorder in which the body cannot process certain types or mucopolysaccharides. When the body cannot process certain types of mucopolysaccharides, they build up or are eliminated, causing various symptoms. It is usually an inherited disease.


==Historical Perspective==
==Historical Perspective==

Latest revision as of 18:12, 1 August 2018

WikiDoc Resources for Morquio's syndrome

Articles

Most recent articles on Morquio's syndrome

Most cited articles on Morquio's syndrome

Review articles on Morquio's syndrome

Articles on Morquio's syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Morquio's syndrome

Images of Morquio's syndrome

Photos of Morquio's syndrome

Podcasts & MP3s on Morquio's syndrome

Videos on Morquio's syndrome

Evidence Based Medicine

Cochrane Collaboration on Morquio's syndrome

Bandolier on Morquio's syndrome

TRIP on Morquio's syndrome

Clinical Trials

Ongoing Trials on Morquio's syndrome at Clinical Trials.gov

Trial results on Morquio's syndrome

Clinical Trials on Morquio's syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Morquio's syndrome

NICE Guidance on Morquio's syndrome

NHS PRODIGY Guidance

FDA on Morquio's syndrome

CDC on Morquio's syndrome

Books

Books on Morquio's syndrome

News

Morquio's syndrome in the news

Be alerted to news on Morquio's syndrome

News trends on Morquio's syndrome

Commentary

Blogs on Morquio's syndrome

Definitions

Definitions of Morquio's syndrome

Patient Resources / Community

Patient resources on Morquio's syndrome

Discussion groups on Morquio's syndrome

Patient Handouts on Morquio's syndrome

Directions to Hospitals Treating Morquio's syndrome

Risk calculators and risk factors for Morquio's syndrome

Healthcare Provider Resources

Symptoms of Morquio's syndrome

Causes & Risk Factors for Morquio's syndrome

Diagnostic studies for Morquio's syndrome

Treatment of Morquio's syndrome

Continuing Medical Education (CME)

CME Programs on Morquio's syndrome

International

Morquio's syndrome en Espanol

Morquio's syndrome en Francais

Business

Morquio's syndrome in the Marketplace

Patents on Morquio's syndrome

Experimental / Informatics

List of terms related to Morquio's syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief:

Morquio's syndrome
ICD-10 E76.2
ICD-9 277.5
OMIM 253000 253010
DiseasesDB 30807 Template:DiseasesDB2
MedlinePlus 001206
eMedicine ped/1477 
MeSH D009085

Overview

Morquio syndrome (referred to as mucopolysaccharidosis IV or Morquio) is a mucopolysaccharide storage disease (see also lysosomal storage disorder), usually inherited. Morquio is a relatively rare metabolic disorder in which the body cannot process certain types or mucopolysaccharides. When the body cannot process certain types of mucopolysaccharides, they build up or are eliminated, causing various symptoms. It is usually an inherited disease.

Historical Perspective

Classification

Presentation

The disease is caused by an abnormal accumulation of mucopolysaccharides - in this case, keratan sulfate - in the body. Keratan sulfate is excreted in urine.

The symptoms vary from patient to patient, and may include hearing loss, cataracts, skeletal dysplasia, spinal instability, and minor respiratory issues, among others.

Types

Two forms are recognized, type A and type B.

Pathophysiology

Causes

Differentiating Morquio's syndrome from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

History and Symptoms

History

The condition was first described, simultaneously and independently, in 1929, by Luis Morquio in Montevideo, Uruguay, and by James Frederick Brailsford in Birmingham, England. They both recognized the occurrence of corneal clouding, aortic valve disease, and urinary excretion of keratan sulfate. Morquio observed the disorder in 4 siblings in a family of Swedish extraction and reported his observations in French.

Symptoms

The following symptoms are associated with Morquio syndrome:

  • Abnormal heart development
  • Abnormal skeletal development
  • Hypermobile joints
  • Large fingers
  • Knock-knees
  • Widely spaced teeth
  • Coarse facial features
  • Large head
  • Star shaped chest (ribs flared)
  • Compression of spinal cord

Complications

Prognosis

Diagnosis

Diagnostic Criteria

Laboratory diagnosis

As most mucopolysaccharidoses, Morquio syndrome exhibits alterations in white blood cells that are diagnostic, and might allow for screening procedures and cost-effective differential diagnosis in the future. These anomalies can be best studied with Wright stain, the routine dye employed in hematology laboratory. Neutrophils in Morquio's syndrome exhibit persistence of the azurophilia in its granules, which is explained by the deficient enzyme's inability to clear them from mucopolysaccharides used as a tags in the cells vesicular sorting system. Approximately 70 percent of the neutrophils exhibit this subtle alteration. Differential diagnosis must be made with mucopolisaccharidoses I,II,III,VI and VII.

Nonetheless, after this screening procedure has been carried on, quantitative enzyme determination assays must be conducted to verify the diagnosis, should any replacement treatment is available.


Complications

Complications that may develop include:

  • Heart failure
  • Difficulty with vision
  • Walking problems related to abnormal curvature of the spine
  • Abnormal neck bones can cause spinal cord damage that can cause severe disease including paralysis if not caught early -- spinal fusion can prevent this
  • Problems with urination

Physical Examination

Laboratory Findings

X-ray

  • Radiographic features include oval-shaped vertebral bodies with anterior beaking, unossified femoral heads with proximal femoral valgus deformities, and broad, flat ilia.
  • By 2 to 3 years of age, universal platyspondyly with central beaking is almost pathognomonic.
  • The long tubular bones are thickened and shortened as well.


Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

External links

References

Template:Endocrine, nutritional and metabolic pathology fi:Morquion oireyhtymä


Template:WikiDoc Sources